GenScience Acquires Rights to Prostate Cancer Therapy in $132 Million Agreement
publication date: Nov 17, 2020
GenScience Pharma acquired China rights to two long-acting depot delivery devices for prostate cancer from Foresee Pharma of Taiwan in a $132 million agreement. The ready-to-use subcutaneous 6-month and 3-month depot formulations, Camcevi™, which will deliver leuprolide mesylate, are currently under review for approval in the US and EU. GenSci will pay $8 million upfront and up to $124 million n milestones, plus royalties. GenSci is a wholly owned subsidiary of Changchun High-Tech Industry. More details....
Stock Symbols: (TWO: 6576) (SHZ: 000661)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.